Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 8/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659639 | 0.94 | ALB (0.58) | PPARDALBMAOBXDH | |
| SCHEMBL3658180 | 0.94 | ALB (0.58) | PPARDALBMAOBXDH | |
| SCHEMBL21052036 | 0.88 | PPARD (0.74) | PPARDALDH1A1MAOB | |
| SCHEMBL3655650 | 0.87 | MCL1 (0.53) | PPARDALBCA12CA1CA2 | |
| SCHEMBL15787044 | 0.87 | ALDH1A1 (0.50) | PPARDALBALDH1A1TSHRFFAR1 | |
| SCHEMBL3904366 | 0.85 | CA12 (0.52) | PPARDCA12ALDH1A1CA1CA2 | |
| SCHEMBL11044502 | 0.85 | PPARD (0.55) | PPARDCA12ALDH1A1CA1CA2 | |
| SCHEMBL538636 | 0.85 | PPARD (0.58) | PPARDTSHRMAOB | |
| SCHEMBL3658911 | 0.84 | PPARD (0.54) | PPARDCA12ALDH1A1CA1CA2 | |
| SCHEMBL11454147 | 0.84 | PPARD (0.61) | PPARDCA12ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7330569-A | — | — | None | — | — | JP | disclosed |
| US-9364424-B2 | Topical cosmetic skin lightening compositions and methods of use thereof | STIEFEL LABORATORIES, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160074315-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. | 2016-03-17 | — | — | US | disclosed |
| EP-2219600-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009067095-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| JP-H07330569-A | BEAUTIFYING COSMETIC | KAO CORP | 1995-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | PPARD 1782/4885ALB 388/4885CA12 1711/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | PPARD 1840/4885ALB 2719/4885CA12 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.